Skip to main content
Top

Open Access 28-10-2024 | Chronic Inflammatory Bowel Disease | REVIEW

Abdominal Pain in Inflammatory Bowel Disease-Epidemiology, Pathophysiology, and Management: A Narrative Review

Authors: Wei-wei Tan, Zi-xuan Liu, Xiao-Yan Liu, Wei-bing Zhang, Lie Zheng, Ya-Li Zhang, Yan-Cheng Dai

Published in: Pain and Therapy

Login to get access

Abstract

Abdominal pain is a major symptom of inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, and has a significant impact on patients’ quality of life. Given the evolving understanding of IBD pathology and management strategies, there is an urgent need to review the recent research findings. In this review, we have analyzed the epidemiology, pathophysiology, and management of abdominal pain in IBD over the past decade. We draw on the current literature and highlight emerging trends, challenges, and advances in this field. By synthesizing key findings, this review provides insights into the complex interplay between abdominal pain, disease progression, and therapeutic interventions for IBD.
Literature
8.
go back to reference Jozwiak-Bebenista M, Nowak JZ. Paracetamol: mechanism of action, applications and safety concern. Acta Pol Pharm. 2014;71:11–23.PubMed Jozwiak-Bebenista M, Nowak JZ. Paracetamol: mechanism of action, applications and safety concern. Acta Pol Pharm. 2014;71:11–23.PubMed
11.
go back to reference Szigethy E. Pain management in patients with inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2018;14:53–6.PubMed Szigethy E. Pain management in patients with inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2018;14:53–6.PubMed
12.
go back to reference Hiraoka S, Fujiwara A, Toyokawa T, Higashi R, Moritou Y, Takagi S, Matsueda K, Suzuki S, Miyaike J, Inokuchi T, Takahara M, Kato J, Okada H. Multicenter survey on mesalamine intolerance in patients with ulcerative colitis. J Gastroenterol Hepatol. 2021;36:137–43. https://doi.org/10.1111/jgh.15138.CrossRefPubMed Hiraoka S, Fujiwara A, Toyokawa T, Higashi R, Moritou Y, Takagi S, Matsueda K, Suzuki S, Miyaike J, Inokuchi T, Takahara M, Kato J, Okada H. Multicenter survey on mesalamine intolerance in patients with ulcerative colitis. J Gastroenterol Hepatol. 2021;36:137–43. https://​doi.​org/​10.​1111/​jgh.​15138.CrossRefPubMed
16.
go back to reference Ananthakrishnan AN, Xavier RJ, Podolsky DK: Inflammatory bowel diseases : a clinician's guide. Chichester, West Sussex, UK ; Hoboken, NJ, John Wiley & Sons, Inc.,; 2017; pp. 27+41. Ananthakrishnan AN, Xavier RJ, Podolsky DK: Inflammatory bowel diseases : a clinician's guide. Chichester, West Sussex, UK ; Hoboken, NJ, John Wiley & Sons, Inc.,; 2017; pp. 27+41.
25.
27.
32.
go back to reference Vork L, Keszthelyi D, van Kuijk SMJ, Quetglas EG, Tornblom H, Simren M, Aziz Q, Corsetti M, Tack J, Mujagic Z, Leue C, Kruimel JW, Masclee AAM. Patient-specific stress-abdominal pain interaction in irritable bowel syndrome: an exploratory experience sampling method study. Clin Transl Gastroenterol. 2020;11:e00209. https://doi.org/10.14309/ctg.0000000000000209 Vork L, Keszthelyi D, van Kuijk SMJ, Quetglas EG, Tornblom H, Simren M, Aziz Q, Corsetti M, Tack J, Mujagic Z, Leue C, Kruimel JW, Masclee AAM. Patient-specific stress-abdominal pain interaction in irritable bowel syndrome: an exploratory experience sampling method study. Clin Transl Gastroenterol. 2020;11:e00209. https://​doi.​org/​10.​14309/​ctg.​0000000000000209​
34.
go back to reference Janssen LM, Rezazadeh Ardabili A, Romberg-Camps MJL, Winkens B, van den Broek RJ, Hulst J, Verwijs HJA, Keszthelyi D, Jonkers D, van Bodegraven AA, Pierik MJ, Mujagic Z. Abdominal pain in patients with inflammatory bowel disease in remission: a prospective study on contributing factors. Aliment Pharmacol Ther. 2023;58:1041–51. https://doi.org/10.1111/apt.17718.CrossRefPubMed Janssen LM, Rezazadeh Ardabili A, Romberg-Camps MJL, Winkens B, van den Broek RJ, Hulst J, Verwijs HJA, Keszthelyi D, Jonkers D, van Bodegraven AA, Pierik MJ, Mujagic Z. Abdominal pain in patients with inflammatory bowel disease in remission: a prospective study on contributing factors. Aliment Pharmacol Ther. 2023;58:1041–51. https://​doi.​org/​10.​1111/​apt.​17718.CrossRefPubMed
36.
go back to reference Irvine EJ, Zhou Q, Thompson AK. The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn’s Relapse Prevention Trial. Am J Gastroenterol. 1996;91:1571–8.PubMed Irvine EJ, Zhou Q, Thompson AK. The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn’s Relapse Prevention Trial. Am J Gastroenterol. 1996;91:1571–8.PubMed
49.
go back to reference Matsumoto K, Sugimoto F, Mizuno T, Hayashi T, Okamura R, Nishioka T, Yasuda H, Horie S, Kido MA, Kato S. Immunohistochemical characterization of transient receptor potential vanilloid types 2 and 1 in a trinitrobenzene sulfonic acid-induced rat colitis model with visceral hypersensitivity. Cell Tissue Res. 2023;391:287–303. https://doi.org/10.1007/s00441-022-03723-9.CrossRefPubMed Matsumoto K, Sugimoto F, Mizuno T, Hayashi T, Okamura R, Nishioka T, Yasuda H, Horie S, Kido MA, Kato S. Immunohistochemical characterization of transient receptor potential vanilloid types 2 and 1 in a trinitrobenzene sulfonic acid-induced rat colitis model with visceral hypersensitivity. Cell Tissue Res. 2023;391:287–303. https://​doi.​org/​10.​1007/​s00441-022-03723-9.CrossRefPubMed
51.
go back to reference Dubinsky MC, Clemow DB, Hunter Gibble T, Li X, Vermeire S, Hisamatsu T, Travis SPL. Clinical effect of mirikizumab treatment on bowel urgency in patients with moderately to severely active ulcerative colitis and the clinical relevance of bowel urgency improvement for disease remission. Crohns Colitis. 2023;5:44. https://doi.org/10.1093/crocol/otac044.CrossRef Dubinsky MC, Clemow DB, Hunter Gibble T, Li X, Vermeire S, Hisamatsu T, Travis SPL. Clinical effect of mirikizumab treatment on bowel urgency in patients with moderately to severely active ulcerative colitis and the clinical relevance of bowel urgency improvement for disease remission. Crohns Colitis. 2023;5:44. https://​doi.​org/​10.​1093/​crocol/​otac044.CrossRef
54.
go back to reference Keohane J, O’Mahony C, O’Mahony L, O’Mahony S, Quigley EM, Shanahan F. Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation? Am J Gastroenterol. 2010;105(1788):1789–94. https://doi.org/10.1038/ajg.2010.156.CrossRef Keohane J, O’Mahony C, O’Mahony L, O’Mahony S, Quigley EM, Shanahan F. Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation? Am J Gastroenterol. 2010;105(1788):1789–94. https://​doi.​org/​10.​1038/​ajg.​2010.​156.CrossRef
58.
64.
go back to reference Vich Vila A, Imhann F, Collij V, Jankipersadsing SA, Gurry T, Mujagic Z, Kurilshikov A, Bonder MJ, Jiang X, Tigchelaar EF, Dekens J, Peters V, Voskuil MD, Visschedijk MC, van Dullemen HM, Keszthelyi D, Swertz MA, Franke L, Alberts R, Festen EAM, Dijkstra G, Masclee AAM, Hofker MH, Xavier RJ, Alm EJ, Fu J, Wijmenga C, Jonkers D, Zhernakova A, Weersma RK. Gut microbiota composition and functional changes in inflammatory bowel disease and irritable bowel syndrome. Sci Transl Med. 2018. https://doi.org/10.1126/scitranslmed.aap8914.CrossRefPubMed Vich Vila A, Imhann F, Collij V, Jankipersadsing SA, Gurry T, Mujagic Z, Kurilshikov A, Bonder MJ, Jiang X, Tigchelaar EF, Dekens J, Peters V, Voskuil MD, Visschedijk MC, van Dullemen HM, Keszthelyi D, Swertz MA, Franke L, Alberts R, Festen EAM, Dijkstra G, Masclee AAM, Hofker MH, Xavier RJ, Alm EJ, Fu J, Wijmenga C, Jonkers D, Zhernakova A, Weersma RK. Gut microbiota composition and functional changes in inflammatory bowel disease and irritable bowel syndrome. Sci Transl Med. 2018. https://​doi.​org/​10.​1126/​scitranslmed.​aap8914.CrossRefPubMed
72.
go back to reference Rousseaux C, Thuru X, Gelot A, Barnich N, Neut C, Dubuquoy L, Dubuquoy C, Merour E, Geboes K, Chamaillard M, Ouwehand A, Leyer G, Carcano D, Colombel JF, Ardid D, Desreumaux P. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med. 2007;13:35–7. https://doi.org/10.1038/nm1521.CrossRefPubMed Rousseaux C, Thuru X, Gelot A, Barnich N, Neut C, Dubuquoy L, Dubuquoy C, Merour E, Geboes K, Chamaillard M, Ouwehand A, Leyer G, Carcano D, Colombel JF, Ardid D, Desreumaux P. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med. 2007;13:35–7. https://​doi.​org/​10.​1038/​nm1521.CrossRefPubMed
78.
go back to reference Spagnuolo R, Cosco C, Mancina RM, Ruggiero G, Garieri P, Cosco V, Doldo P. Beta-glucan, inositol and digestive enzymes improve quality of life of patients with inflammatory bowel disease and irritable bowel syndrome. Eur Rev Med Pharmacol Sci. 2017;21:102–7.PubMed Spagnuolo R, Cosco C, Mancina RM, Ruggiero G, Garieri P, Cosco V, Doldo P. Beta-glucan, inositol and digestive enzymes improve quality of life of patients with inflammatory bowel disease and irritable bowel syndrome. Eur Rev Med Pharmacol Sci. 2017;21:102–7.PubMed
79.
go back to reference Chhibba T, Guizzetti L, Seow CH, Lu C, Novak KL, Ananthakrishnan AN, Bernstein CN, Kaplan GG, Panaccione R, Ma C. Frequency of opioid prescription at emergency department discharge in patients with inflammatory bowel disease: a nationwide analysis. Clin Gastroenterol Hepatol. 2021;19(2064–2071):e2061. https://doi.org/10.1016/j.cgh.2020.07.020.CrossRef Chhibba T, Guizzetti L, Seow CH, Lu C, Novak KL, Ananthakrishnan AN, Bernstein CN, Kaplan GG, Panaccione R, Ma C. Frequency of opioid prescription at emergency department discharge in patients with inflammatory bowel disease: a nationwide analysis. Clin Gastroenterol Hepatol. 2021;19(2064–2071):e2061. https://​doi.​org/​10.​1016/​j.​cgh.​2020.​07.​020.CrossRef
80.
go back to reference Baillie S, Limdi JK, Bassi A, Fraser A, Parkes G, Scott G, Raine T, Lamb CA, Kennedy NA, Fumis N, Smith MA, Nicolaou A, Emms H, Wye J, Lehmann A, Carbery I, Goodhand J, Lees R, Beshyah W, Luthra P, Pollok R, Selinger C. Opioid use and associated factors in 1676 patients with inflammatory bowel disease: a multicentre quality improvement project. Frontline Gastroenterol. 2023;14:497–504. https://doi.org/10.1136/flgastro-2023-102423.CrossRefPubMedPubMedCentral Baillie S, Limdi JK, Bassi A, Fraser A, Parkes G, Scott G, Raine T, Lamb CA, Kennedy NA, Fumis N, Smith MA, Nicolaou A, Emms H, Wye J, Lehmann A, Carbery I, Goodhand J, Lees R, Beshyah W, Luthra P, Pollok R, Selinger C. Opioid use and associated factors in 1676 patients with inflammatory bowel disease: a multicentre quality improvement project. Frontline Gastroenterol. 2023;14:497–504. https://​doi.​org/​10.​1136/​flgastro-2023-102423.CrossRefPubMedPubMedCentral
82.
go back to reference Lindstrom BF, Ruckle JL, Turner SA, Stauber K, Brierley SM, English BA, Yacyshyn B. P139 Olorinab, a peripherally restricted, highly selective agonist of the cannabinoid receptor type 2 for the management of visceral pain in inflammatory bowel disease (IBD)—preclinical and early clinical development. Gastroenterology. 2019;156:S92–3. https://doi.org/10.1053/j.gastro.2019.01.215.CrossRef Lindstrom BF, Ruckle JL, Turner SA, Stauber K, Brierley SM, English BA, Yacyshyn B. P139 Olorinab, a peripherally restricted, highly selective agonist of the cannabinoid receptor type 2 for the management of visceral pain in inflammatory bowel disease (IBD)—preclinical and early clinical development. Gastroenterology. 2019;156:S92–3. https://​doi.​org/​10.​1053/​j.​gastro.​2019.​01.​215.CrossRef
83.
go back to reference Yacyshyn BR, Hanauer S, Klassen P, English BA, Stauber K, Barish CF, Gilder K, Turner S, Higgins PDR. Safety, pharmacokinetics, and efficacy of olorinab, a peripherally acting, highly selective, full agonist of the cannabinoid receptor 2, in a phase 2a study of patients with chronic abdominal pain associated with Crohn's disease. Crohns Colitis. 2021;3:89. https://doi.org/10.1093/crocol/otaa089.CrossRef Yacyshyn BR, Hanauer S, Klassen P, English BA, Stauber K, Barish CF, Gilder K, Turner S, Higgins PDR. Safety, pharmacokinetics, and efficacy of olorinab, a peripherally acting, highly selective, full agonist of the cannabinoid receptor 2, in a phase 2a study of patients with chronic abdominal pain associated with Crohn's disease. Crohns Colitis. 2021;3:89. https://​doi.​org/​10.​1093/​crocol/​otaa089.CrossRef
84.
go back to reference D’Haens G, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, Dubinsky M, Feagan BG, Hisamatsu T, Lim A, Lindsay JO, Loftus EV Jr, Panes J, Peyrin-Biroulet L, Ran Z, Rubin DT, Sandborn WJ, Schreiber S, Neimark E, Song A, Kligys K, Pang Y, Pivorunas V, Berg S, Duan WR, Huang B, Kalabic J, Liao X, Robinson A, Wallace K, Ferrante M. Risankizumab as induction therapy for Crohn’s disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022;399:2015–30. https://doi.org/10.1016/S0140-6736(22)00467-6.CrossRefPubMed D’Haens G, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, Dubinsky M, Feagan BG, Hisamatsu T, Lim A, Lindsay JO, Loftus EV Jr, Panes J, Peyrin-Biroulet L, Ran Z, Rubin DT, Sandborn WJ, Schreiber S, Neimark E, Song A, Kligys K, Pang Y, Pivorunas V, Berg S, Duan WR, Huang B, Kalabic J, Liao X, Robinson A, Wallace K, Ferrante M. Risankizumab as induction therapy for Crohn’s disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022;399:2015–30. https://​doi.​org/​10.​1016/​S0140-6736(22)00467-6.CrossRefPubMed
86.
89.
go back to reference Palumbo VD, Romeo M, Marino Gammazza A, Carini F, Damiani P, Damiano G, Buscemi S, Lo Monte AI, Gerges-Geagea A, Jurjus A, Tomasello G. The long-term effects of probiotics in the therapy of ulcerative colitis: a clinical study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016;160:372–7. https://doi.org/10.5507/bp.2016.044.CrossRefPubMed Palumbo VD, Romeo M, Marino Gammazza A, Carini F, Damiani P, Damiano G, Buscemi S, Lo Monte AI, Gerges-Geagea A, Jurjus A, Tomasello G. The long-term effects of probiotics in the therapy of ulcerative colitis: a clinical study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016;160:372–7. https://​doi.​org/​10.​5507/​bp.​2016.​044.CrossRefPubMed
97.
go back to reference Schmulson MJ, Chiu-Ugalde J, Saez-Rios A, Lopez-Colombo A, Mateos-Perez GJ, Remes-Troche JM, Sobrino-Cossio S, Soto-Perez JC, de la Tamayo Cuesta JL, Teramoto-Matsubara OT, Lopez-Alvarenga JC. Efficacy of the combination of pinaverium bromide 100 mg plus simethicone 300 mg in abdominal pain and bloating in irritable bowel syndrome: a randomized, placebo-controlled trial. J Clin Gastroenterol. 2020;54:e30–9. https://doi.org/10.1097/MCG.0000000000001242.CrossRefPubMed Schmulson MJ, Chiu-Ugalde J, Saez-Rios A, Lopez-Colombo A, Mateos-Perez GJ, Remes-Troche JM, Sobrino-Cossio S, Soto-Perez JC, de la Tamayo Cuesta JL, Teramoto-Matsubara OT, Lopez-Alvarenga JC. Efficacy of the combination of pinaverium bromide 100 mg plus simethicone 300 mg in abdominal pain and bloating in irritable bowel syndrome: a randomized, placebo-controlled trial. J Clin Gastroenterol. 2020;54:e30–9. https://​doi.​org/​10.​1097/​MCG.​0000000000001242​.CrossRefPubMed
99.
go back to reference Zhang S, Zhao L, Shen H, Tang Z, Qin D, Li J, Zhang B, Yang G, Chen M, Wu K, Liu Z, Yang H, Wang H, Zong Y, Chen Y, Xiao S, Cai Q. International clinical practice guideline on the use of traditional Chinese medicine for ulcerative colitis by Board of Specialty Committee of Digestive System Disease of World Federation of Chinese Medicine Societies (2023). Phytother Res. 2024;38:970–99. https://doi.org/10.1002/ptr.8087.CrossRefPubMed Zhang S, Zhao L, Shen H, Tang Z, Qin D, Li J, Zhang B, Yang G, Chen M, Wu K, Liu Z, Yang H, Wang H, Zong Y, Chen Y, Xiao S, Cai Q. International clinical practice guideline on the use of traditional Chinese medicine for ulcerative colitis by Board of Specialty Committee of Digestive System Disease of World Federation of Chinese Medicine Societies (2023). Phytother Res. 2024;38:970–99. https://​doi.​org/​10.​1002/​ptr.​8087.CrossRefPubMed
101.
go back to reference Xu J, Xi Y. Observation on the efficacy of Chinese medicine dialectic treatment of ulcerative colitis (in Chinese). Chin Gen Pract. 2023;26:41–3. Xu J, Xi Y. Observation on the efficacy of Chinese medicine dialectic treatment of ulcerative colitis (in Chinese). Chin Gen Pract. 2023;26:41–3.
103.
113.
go back to reference de Graaf MCG, Spooren C, Hendrix EMB, Hesselink MAM, Feskens EJM, Smolinska A, Keszthelyi D, Pierik MJ, Mujagic Z, Jonkers D. Diet quality and dietary inflammatory index in Dutch inflammatory bowel disease and irritable bowel syndrome patients. Nutrients. 2022;14:8. https://doi.org/10.3390/nu14091945.CrossRef de Graaf MCG, Spooren C, Hendrix EMB, Hesselink MAM, Feskens EJM, Smolinska A, Keszthelyi D, Pierik MJ, Mujagic Z, Jonkers D. Diet quality and dietary inflammatory index in Dutch inflammatory bowel disease and irritable bowel syndrome patients. Nutrients. 2022;14:8. https://​doi.​org/​10.​3390/​nu14091945.CrossRef
115.
go back to reference Tapete G, De Bortoli N, Ceccarelli L, Mumolo MG, Vinci E, Albano E, Bertani L, Di Fluri G, Laino G, Ricchiuti A, Bellini M, Marchi S, Costa F. P.07.6 low-fodmaps diet improves intestinal symptoms in ibd patients with disease remission: randomized case-control study. Digest Liver Dis. 2018. https://doi.org/10.1016/s1590-8658(18)30556-5.CrossRef Tapete G, De Bortoli N, Ceccarelli L, Mumolo MG, Vinci E, Albano E, Bertani L, Di Fluri G, Laino G, Ricchiuti A, Bellini M, Marchi S, Costa F. P.07.6 low-fodmaps diet improves intestinal symptoms in ibd patients with disease remission: randomized case-control study. Digest Liver Dis. 2018. https://​doi.​org/​10.​1016/​s1590-8658(18)30556-5.CrossRef
116.
go back to reference Tapete G, Ceccarelli L, De Bortoli N, Bertani L, Albano E, Svizzero GB, Di Fluri G, Guidi G, Mumolo MG, Marchi S, Costa F. P.06.16 low- versus high-fodmaps diet in controlling residual abdominal symptoms in inflammatory bowel disease patients: a randomized study with crossing over. Digest Liver Dis. 2019;51:85. https://doi.org/10.1016/s1590-8658(19)30446-3.CrossRef Tapete G, Ceccarelli L, De Bortoli N, Bertani L, Albano E, Svizzero GB, Di Fluri G, Guidi G, Mumolo MG, Marchi S, Costa F. P.06.16 low- versus high-fodmaps diet in controlling residual abdominal symptoms in inflammatory bowel disease patients: a randomized study with crossing over. Digest Liver Dis. 2019;51:85. https://​doi.​org/​10.​1016/​s1590-8658(19)30446-3.CrossRef
127.
go back to reference Stapersma L, van den Brink G, van der Ende J, Szigethy EM, Beukers R, Korpershoek TA, Theuns-Valks SDM, Hillegers MHJ, Escher JC, Utens E. Effectiveness of disease-specific cognitive behavioral therapy on anxiety, depression, and quality of life in youth with inflammatory bowel disease: a randomized controlled trial. J Pediatr Psychol. 2018;43:967–80. https://doi.org/10.1093/jpepsy/jsy029.CrossRefPubMedPubMedCentral Stapersma L, van den Brink G, van der Ende J, Szigethy EM, Beukers R, Korpershoek TA, Theuns-Valks SDM, Hillegers MHJ, Escher JC, Utens E. Effectiveness of disease-specific cognitive behavioral therapy on anxiety, depression, and quality of life in youth with inflammatory bowel disease: a randomized controlled trial. J Pediatr Psychol. 2018;43:967–80. https://​doi.​org/​10.​1093/​jpepsy/​jsy029.CrossRefPubMedPubMedCentral
128.
go back to reference van den Brink G, Stapersma L, Bom AS, Rizopolous D, van der Woude CJ, Stuyt RJL, Hendriks DM, van der Burg JAT, Beukers R, Korpershoek TA, Theuns-Valks SDM, Utens E, Escher JC. Effect of cognitive behavioral therapy on clinical disease course in adolescents and young adults with inflammatory bowel disease and subclinical anxiety and/or depression: results of a randomized trial. Inflamm Bowel Dis. 2019;25:1945–56. https://doi.org/10.1093/ibd/izz073.CrossRefPubMedPubMedCentral van den Brink G, Stapersma L, Bom AS, Rizopolous D, van der Woude CJ, Stuyt RJL, Hendriks DM, van der Burg JAT, Beukers R, Korpershoek TA, Theuns-Valks SDM, Utens E, Escher JC. Effect of cognitive behavioral therapy on clinical disease course in adolescents and young adults with inflammatory bowel disease and subclinical anxiety and/or depression: results of a randomized trial. Inflamm Bowel Dis. 2019;25:1945–56. https://​doi.​org/​10.​1093/​ibd/​izz073.CrossRefPubMedPubMedCentral
129.
go back to reference Levy RL, van Tilburg MA, Langer SL, Romano JM, Walker LS, Mancl LA, Murphy TB, Claar RL, Feld SI, Christie DL, Abdullah B, DuPen MM, Swanson KS, Baker MD, Stoner SA, Whitehead WE. Effects of a cognitive behavioral therapy intervention trial to improve disease outcomes in children with inflammatory bowel disease. Inflamm Bowel Dis. 2016;22:2134–48. https://doi.org/10.1097/MIB.0000000000000881.CrossRefPubMed Levy RL, van Tilburg MA, Langer SL, Romano JM, Walker LS, Mancl LA, Murphy TB, Claar RL, Feld SI, Christie DL, Abdullah B, DuPen MM, Swanson KS, Baker MD, Stoner SA, Whitehead WE. Effects of a cognitive behavioral therapy intervention trial to improve disease outcomes in children with inflammatory bowel disease. Inflamm Bowel Dis. 2016;22:2134–48. https://​doi.​org/​10.​1097/​MIB.​0000000000000881​.CrossRefPubMed
130.
go back to reference Torres J, Ellul P, Langhorst J, Mikocka-Walus A, Barreiro-de Acosta M, Basnayake C, Ding NJS, Gilardi D, Katsanos K, Moser G, Opheim R, Palmela C, Pellino G, Van der Marel S, Vavricka SR. European Crohn's and Colitis Organisation topical review on complementary medicine and psychotherapy in inflammatory bowel disease. J Crohns Colitis. 2019;13:673–685e. https://doi.org/10.1093/ecco-jcc/jjz051.CrossRefPubMed Torres J, Ellul P, Langhorst J, Mikocka-Walus A, Barreiro-de Acosta M, Basnayake C, Ding NJS, Gilardi D, Katsanos K, Moser G, Opheim R, Palmela C, Pellino G, Van der Marel S, Vavricka SR. European Crohn's and Colitis Organisation topical review on complementary medicine and psychotherapy in inflammatory bowel disease. J Crohns Colitis. 2019;13:673–685e. https://​doi.​org/​10.​1093/​ecco-jcc/​jjz051.CrossRefPubMed
Metadata
Title
Abdominal Pain in Inflammatory Bowel Disease-Epidemiology, Pathophysiology, and Management: A Narrative Review
Authors
Wei-wei Tan
Zi-xuan Liu
Xiao-Yan Liu
Wei-bing Zhang
Lie Zheng
Ya-Li Zhang
Yan-Cheng Dai
Publication date
28-10-2024
Publisher
Springer Healthcare
Published in
Pain and Therapy
Print ISSN: 2193-8237
Electronic ISSN: 2193-651X
DOI
https://doi.org/10.1007/s40122-024-00672-9

Keynote webinar | Spotlight on adolescent vaping

  • Live
  • Webinar | 29-01-2025 | 18:00 (CET)

Live: Wednesday 29th January, 18:00-19:30 CET

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Prof. Ann McNeill
Dr. Debbie Robson
Benji Horwell
Developed by: Springer Medicine
Join the webinar

Keynote webinar | Spotlight on modern management of frailty

Frailty has a significant impact on health and wellbeing, especially in older adults. Our experts explain the factors that contribute to the development of frailty and how you can manage the condition and reduce the risk of disability, dependency, and mortality in your patients.

Prof. Alfonso Cruz-Jentoft
Prof. Barbara C. van Munster
Prof. Mirko Petrovic
Developed by: Springer Medicine
Watch now

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more